Clinical trialRSSToday
A new treatment called Roctavian was given as a single injection to men with severe hemophilia A (a bleeding disorder). Seven years later, most patients had fewer bleeding episodes and needed less preventive medicine. This suggests the treatment's benefits can last for many years.
WHY IT MATTERSIf you have severe hemophilia A, Roctavian could mean switching from frequent infusions or injections to a single treatment that protects you from bleeds for years.
AdvocacyRSSToday
A person recently attended the Hemophilia Federation of America's annual symposium in New Orleans and shared their positive experience meeting others in the hemophilia community. The event inspired reflection on both current progress in treating hemophilia and the difficult history the community has faced. The author expressed gratitude for being included and highlighted the importance of gathering with others who understand the challenges of living with a bleeding disorder.
WHY IT MATTERSCommunity events like the HFA Symposium provide hemophilia patients and caregivers with opportunities to connect with others, learn about new treatments, and access support networks that can improve quality of life and treatment decisions.
NewsRSS2 days ago
A parent shares a personal story about receiving a song recording from their son with hemophilia, reflecting on how their child's talents and abilities extend far beyond his medical condition. The article emphasizes that people living with rare diseases like hemophilia are whole individuals with gifts and passions that deserve recognition. This piece appears in Hemophilia News Today and focuses on the emotional and human side of living with a chronic blood disorder.
WHY IT MATTERSFor parents and caregivers of children with hemophilia, this story validates the importance of seeing their child as a complete person with abilities and dreams, not just defined by their bleeding disorder diagnosis.
AdvocacyRSS2 days ago
World Hemophilia Day on April 17 is highlighting the importance of getting diagnosed early and accurately for hemophilia and other bleeding disorders. Early diagnosis is being emphasized as a crucial first step that helps people with hemophilia manage their condition better and live healthier lives.
WHY IT MATTERSEarly and accurate diagnosis of hemophilia can significantly impact treatment outcomes and quality of life, making this awareness campaign directly relevant to patients seeking to optimize their care.
ResearchRSS2 days ago
A new study shows that regular exercise — including activities like walking, strength training, and balance work — is safe and helpful for people with hemophilia of all ages. The research found that exercise can reduce chronic pain, improve how well people can move and function, and make life better overall. The key is that exercise programs need to be carefully designed for each person's needs.
WHY IT MATTERSPeople with hemophilia often avoid exercise due to bleeding concerns, but this study provides evidence that structured exercise can safely reduce pain and improve daily functioning without increasing bleeding risk.
ResearchRSS2 days ago
Researchers developed an artificial intelligence tool that can accurately detect bleeding inside joints in adults with hemophilia by analyzing ultrasound images. This technology could eventually allow patients to get ultrasound scans at home instead of traveling to a hospital or clinic. Early detection of joint bleeding is important because it helps prevent long-term damage to the joints.
WHY IT MATTERSHemophilia patients currently must travel to medical facilities for ultrasound imaging to detect joint bleeds; this AI tool could enable home-based monitoring, reducing travel burden and potentially catching bleeding episodes earlier.
ResearchPUBMED2 days ago
Researchers in Germany studied health insurance records from 2017-2019 to understand how hemophilia A (a bleeding disorder) affects patients and how much it costs to treat. They found 257 patients with hemophilia A and grouped them by severity—mild, moderate, or severe—based on how much clotting medicine they needed. This study shows that insurance data can help doctors and researchers learn more about rare diseases like hemophilia A.
WHY IT MATTERSIf you have hemophilia A in Germany, this research demonstrates that your health insurance claims data can be used to better understand disease patterns, treatment costs, and care gaps—potentially leading to improved healthcare planning and resource allocation for your condition.
Clinical trialUNITERAREApr 3
This is a clinical trial testing a blood clotting medicine called Nuwiq in women and girls with hemophilia A who need surgery. Hemophilia A is a rare bleeding disorder where the body doesn't make enough of a protein that helps blood clot. The trial will study how well Nuwiq works and what dose is best for these patients during surgical procedures.
WHY IT MATTERSThis trial is specifically designed for women and girls with hemophilia A undergoing surgery — a population that often receives less research attention than males with the same condition.